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Bees@wur is going to test varroa-gate 
together with Dutch beekeepers
Tjeerd Blacquière
Together with Dutch beekeepers Bees@wur of Wageningen UR 
are starting research on the efficacy and safety of a new 
application for the control of varroa mites in honeybee colonies. 
With this research we contribute to the health of bee colonies in Europe. The research is 
aiming to test the “varroa-gate” of Bayer HealthCare Animal Health, the company that 
developed the gate and is intending to register it as a veterinary medicine in Europe. The 
research is part of the legally required research for the registration of a veterinary medicine 
in Europe and financed by Bayer.
For registration in Europe field studies are needed
Before a chemical or product can be registered as a veterinary medicine in Europe or 
member states, an extensive study file with several studies has to be provided, containing 
studies that show that the product is effective, that it is safe and does not cause harmful 
residues (for instance in honey). These field tests are simultaneously performed at different 
apiaries in a number of European countries. Bees@wur is going to perform the Dutch share 
in the field testing together with a number of Dutch beekeepers.
And after that?
Depending on how fast all necessary data in the dossier are available the registration in 
Europe or in member states can be requested. The demands for a registration dossier are 
however extensive and very rigorous, so before the gate will be available for beekeepers 
still a few years may pass by. 
Aim and mode of action of varroa-gate
During a workshop on Bee Health organized by the European Commission on 7th of April 
2014 in Brussels, it was clearly stated that one of the weaknesses of European Beekeeping 
was the lack of proper effective and registered medicines, especially against varroosis. 
Several medicines from the past have lost their effectiveness, and although varroa control 
is possible with ‘soft’ acaricides as oxalic acid, formic acid and thymol, this often fails to be 
effective. In cases in which the ‘soft’ medicine does not control varroa effectively, remaining 
mites can build up a population quickly in the colony, and even re-infest colonies that were 
effectively treated.
This re-infestation was the reason for Bayer HealthCare Animal Health to start some years 
ago with the development and testing of ‘Varroa-gate’: a gate in the hive entrance that 
allows bees to enter and leave the hive, but that would eliminate a mite entering or leaving 
Page 1 of 2Wageningen UR
8-2-2017http://mailing.wageningenur.nl/880/microsite/Wageningen_UR.html?me...
on the back of a bee due to a low dose of an acaricide.
The aim is to prevent mites re-entering clean colonies as well as to prevent mites leaving 
alive from infested hives. About earlier testing of prototypes of the Varroa-gate I reported 
in the former issue of Bijennieuws.
The idea of the Varroa-gate is to continue working as much as possible with these ‘soft’ 
acaricides, but to avoid and compensate their weaknesses by applying in addition a tiny 
amount of a chemical acaricide in the Varroa-gate, and avoiding the development of 
resistance.
Through the low dosage in the gate and the fact that only the forager bees are in contact 
with it, residues in the hive are expected to be negligible. Moreover, by using a different 
chemical in consecutive years resistance development will be avoided. The development of 
the varroa-gate is a follow-up of a range of in-hive applications that have been developed 
by Bayer HealthCare Animal Health since the varroa mite entered Europe (c.f. Perizin, 
Bayvarol, Apistan).
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